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Diabetes in patients with cystic fibrosis (CF) is common but typically does not occur before the age of 10 years. We describe a male with
cystic fibrosis who developed diabetes, consistent with cystic fibrosis related diabetes, at the age of 2 years and treated successfully with insulin.
Published by Elsevier B.V. on behalf of European Cystic Fibrosis Society.1. Introduction
As patients with cystic fibrosis (CF) are now living longer
because of improved medical care, cystic fibrosis related
diabetes (CFRD) has become the leading co-morbidity in
patients with CF [1], with a prevalence of impaired glucose
tolerance of 70% after 20 years of age in one study [2]. The
prevalence of CFRD increases with age with an age-
dependent increase in incidence rate of 5% per year [3]. At
age 30 years, 50% of patients with CF are estimated to have
CFRD, whereas the prevalence of CFRD in patients less than
10 years approaches only 2% [4].
Although CFRD shares features of type 1 and 2 diabetes
mellitus, the etiology and clinical course of CFRD are
unique. There is an obstructive process that leads to
pancreatic fibrosis, along with a component of insulin
resistance, which leads to the development of diabetes in
patients with CF [5]. Genotype–phenotype correlations fail
to directly predict those at risk for developing CFRD [6].
However, genotype as a predictor of pancreatic insufficiency
can help in identifying those at risk for CFRD because of the
association between CFRD and pancreatic insufficiency [7].Abbreviations: CF, Cystic Fibrosis; CFRD, Cystic Fibrosis Related
Diabetes.
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Our patient was a term male weighing 3.6 kg at birth. His
older sister had CF, which prompted testing for CF in this
infant. Sweat test results showed a chloride of 132 meq/
l (abnormalN60 meq/l). Cystic fibrosis transmembrane
conductance regulator gene mutation analysis was per-
formed, and the patient was found to have the heterozygous
presence of the known deleterious mutation, ΔF508 and the
rarer 1471delA mutation, for which little is known.
Pancreatic enzyme replacement and chest physiotherapy
were initiated after diagnosis. At 2.5 months of age, he was
hospitalized for failure to thrive with a weight of −2.473 SD
of the mean for age. Despite high caloric naso-gastric and oral
feeds, he failed to meet his goal weight. He was diagnosed
with gastroesophageal reflux and delayed gastric emptying
and had a subsequent gastrostomy, pyloromyotomy and
Nissen fundoplication. Bolus feeds were then started in the
daytime through the gastrostomy tube. By one year of age,
nocturnal gastrostomy feedings were added to increase daily
calories, while receiving a total pancreatic enzyme replace-
ment dose of 2480 units of Lipase/kg/meal. Despite these
efforts, his weight dropped to 0.2 percentile (−2.85 SD) and
height to 1.7 percentile (−2.13 SD) (Table 1).
By 11 months of age, our patient began requiring
antibiotic treatment for clinical CF exacerbation. At
22 months, during his routine annual CF screening labs, he
had a random serum glucose of 15.6 mmol/L (280 mg/dl), but
insulin was not started. At 23 months, he wore a continuous
glucose monitoring system that indicated significantn Cystic Fibrosis Society.
Table 1
Age Height
(cm)
Weight
(kg)
Weight
(%)
Weight
SDS
Height
(%)
Height
SDS
Height velocity
(cm/yr)
Height velocity
SDS
BMI
(kg/m sq)
BSA
(m sq)
IBW
(kg)
Difference actual
wt to IBW
0 3.65 58.95 0.226
0.1 53.5 4.5 26.66 −0.623 5.11 −1.634 N/A 14.1 0.27 4.8 −0.3
0.14 56.5 4.6 26.66 −0.623 6.12 −1.545 N/A 16.07 0.27 4.2 0.4
0.28 57.5 4.5 0.67 −2.473 3.41 −1.824 5.6 N/A 13.61 0.27 5.1 −0.6
0.53 63.5 6.7 5.3 −1.617 4.54 −1.691 16.3 N/A 16.62 0.35 6.8 −0.1
0.77 65.5 7.9 6.17 −1.541 0.47 −2.593 13.4 N/A 18.41 0.39 7.4 0.5
1.02 70 7.64 0.21 −2.858 1.68 −2.126 14.7 N/A 15.59 0.39 8.8 −1.16
1.27 76 9 2.28 −1.999 14.75 −1.047 24 N/A 15.58 0.44 10.4 −1.4
1.85 80 9.96 1.91 −2.073 4.57 −1.688 12 N/A 15.59 0.47 11.3 −1.34
2.12 81 10.6 3.31 −1.836 3.08 −1.869 10 N/A 16.16 0.49 11.5 −0.9
2.25 82 10.7 2.82 −1.907 2.83 −1.907 7.7 −0.545 15.91 0.5 11.7 −1
2.52 85 11.4 5.29 −1.617 4.53 −1.693 10 1.094 15.78 0.52 12.3 −0.9
2.77 86 12 7.95 −1.408 2.43 −1.972 7.7 −0.387 16.16 0.49 11.5 0.5
3 87.5 12.3 7.26 −1.457 1.84 −2.088 7.2 −0.684 16.07 0.55 12.9 −0.6
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4.83 mmol/L (87 mg/dl) and 16.28 mmol/L (293 mg/dl),
but rarely below 5.56 mmol/L (100 mg/dl) (see Fig. 1). At
that time he had aHemoglobin A1c of 5.9%, and undetectable
Islet cell and Anti-GAD65 antibodies (b10 JDF and
b0.5 units/ml respectively).
At 24 months, our patient was started on insulin therapy
for diabetes with Aspart insulin with meals, 1 unit for every
25 g of carbohydrates, but no basal (NPH or glargine)
insulin. Nighttime continuous feeds were discontinued
because of concern of hypoglycemia with accidental
interruption of feeds. At follow-up visits, the patient
demonstrated consistent and improved weight gain. Care-
givers were adherent to therapy, sometimes injecting as
many as 10 shots daily corresponding with the frequency of
meals and snacks. Because of the frequency of injections, heFig. 1. Glucose readings by continuous glucose monitoring devwas transitioned to a continuous insulin pump at 2.5 years of
age. He was put on a continuous basal infusion rate of 0.05 u/
h and a carbohydrate ratio of 1 unit for every 20 g of
carbohydrates. By his third birthday, his weight was above
the 5th percentile (7.3 percentile, −1.5 SD), he was growing
at 7.2 cm/year (24.7 percentile, −0.7 SD), and his
Hemoglobin A1c was 5.6%. Despite being off of nocturnal
gastrostomy feeds since he was diagnosed with diabetes, he
has continued to consistently gain weight.
3. Discussion
Cystic fibrosis related diabetes is an insidious complica-
tion of CF that may present with weight loss or poor weight
gain and typically in older children and adults with CF.
Treatment with insulin has been shown to reverse the declineice before and during continuous insulin pump therapy.
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CFRD [8]. There are a few reported cases of CFRD in very
young children with CF, with the youngest reported case
occurring at 6 months [9], and another report of a newborn
with transient diabetes that later developed impaired glucose
tolerance [10]. There are no studies or reported cases that
report treatment of CFRD in the extremely young patients
with CF. There are also no standards for screening CF
patients for diabetes at this early age.
We report a case of a 2-year old with known cystic
fibrosis and failure to thrive from early infancy despite early
diagnosis of CF and routine treatment with pancreatic
enzyme replacement. Our patient is an example of how
CFRD might present in an infant with failure to thrive
despite aggressive intervention with both enzyme replace-
ment and gastrostomy feedings. Although patients with both
CF and type 1 diabetes are expected to occur in the same
individual as a rare chance occurrence, the unusual genotype
mutation, absence of autoimmunity, and the delay in insulin
requirements after diagnosis in this child suggest that under
certain circumstances, bonafide CFRD can occur in the very
young child with CF. Most importantly, aggressive treatment
with intensive insulin therapy at this young age, at least in
our patient, has shown to prevent weight loss and promote
weight gain. Furthermore, screening for CFRD in any infant,
child or adult with CF who fails to meet weight goals should
be considered a standard of care.References
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